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Mafosfamide cyclohexylamine salt (D-17272), 4-hydro-peroxy-cyclophosphamide (D-18864)
and glufosfamide (D-19575, $-D-glucose-isophosphoramide mustard) are new generation
oxazaphosphorine agents. The present investigation was undertaken to determine the activity
of these three oxazaphosphorines in human promyelocytic leukemia HL-60 cells. The research
was conducted using the spectrophotometric MTT assay and the electronic Beckman Coulter
and microscopy methods. Functional and morphological changes were observed after
exposure of HL-60 cells to the oxazaphosphorine agents. The various patterns of temporary
alterations in cell viability, size and count, and also in the frequency of leukemic cells
undergoing mitotic catastrophe, apoptosis and necrosis, were shown. Different leukemic cell
responses to the action of the three oxazaphosphorines were evaluated. These are the first
data comparing the in vitro activity of D-17272, D-18864 and D-19575 against human
promyelocytic leukemia cells.
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Oxazaphosphorines represent an important class
of anticancer alkylating agents. Cyclophospha-
mide, ifosfamide and trofosfamide are commonly
used in the treatment of a wide variety of solid tu-
mors and hematological malignancies. New gen-
eration oxazaphosphorine agents have been devel-
oped in an attempt to improve the efficacy of che-
motherapy. Mafosfamide cyclohexylamine salt,
4-hydro-peroxy-cyclophosphamide and glufosfa-
mide (Fig. 1) are new oxazaphosphorines. An as-
sessment of the activity of these alkylating agents
against pathological cells is of key importance in
chemotherapy (STYCZYÑSKI et al. 2002a; ZHANG
et al. 2005a; LIANG et al. 2007; JACOB et al. 2008;
GIRAUD et al. 2010; MAZUR et al. 2011, 2012a).
Cell viability, mitotic catastrophe, cell death,
and cell size and count are accepted important pa-
rameters for determining and characterizing the
anticancer activity of various chemotherapeutic
agents (ROSS 1976, 1981a, 1981b; KASPERS et al.
1995; MAKIN & HICKMAN 2000; BECKER et al.
2002; BORST & ROTTENBERG 2004; MANSILLA
et al. 2006; RICCI & ZONG 2006; DE BRUIN &
MEDEMA 2008; SUN & PENG 2009). Neverthe-
less, available information on the antileukemic po-
tential of the new oxazaphosphorines is scarce.
The in vitro activity of mafosfamide cyclo-
hexylamine salt, glufosfamide, and 4-hydro-
peroxy-cyclophosphamide has only been studied
in childhood acute leukemia cells, human lympho-
blastoid cells, human histiocytic lymphoma U937
cells, human acute lymphoblastic leukemia
MOLT-4 cells, and human acute myeloblastic leu-
kemia ML-1 cells (STYCZYÑSKI et al. 2006b;
GOLDSTEIN et al. 2008; MAZUR et al. 2009, 2010,
2012b; OPYDO-CHANEK et al. 2010, 2011).
_______________________________________
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The leukemic cell response to the action of the new
oxazaphosphorines has not yet been completely
explained and is still under investigation.
The aim of the present investigation was to
evaluate and compare the in vitro activities of ma-
fosfamide cyclohexylamine salt, 4-hydro-peroxy-
cyclophosphamide and glufosfamide, against hu-
man promyelocytic leukemia HL-60 cells. After
oxazaphosphorine application, temporary changes
in leukemic cell viability, size and count and also
in the frequency of HL-60 cells undergoing mitotic
catastrophe, i.e. the process preceding cell death
(MANSILLA et al. 2006), and two major types of
programmed death, apoptosis and necrosis (KAUF-
MANN & EARNSHAW 2000; MAKIN & HICKMAN
2000; BORST & ROTTENBERG 2004; HENDRIQUEZ
et al. 2008; SUN & PENG 2009), were analyzed.
Material and Methods
Cells
Human promyelocytic leukemia HL-60 cells
(American Type Culture Collection, Rockville,
MD, USA) were maintained in RPMI 1640 me-
dium (Gibco BRL Life Technologies), supple-
mented with 10% fetal calf serum (GIBCO BRL
Life Technologies), 2 mM L-glutamine (Sigma
Aldrich), and antibiotic antimycotic solution
(AAS, Sigma Aldrich). AAS contained 20 units of
penicillin, 20Fg streptomycin and 0.05Fg ampho-
tericin B. Every third day, HL-60 cells were pas-
saged. The cells grew at 37oC in an atmosphere of
5% CO2 in air (HERAcell incubator, KendroLab).
Chemicals
Mafosfamide cyclohexylamine salt (D-17272),
4-hydro-peroxy-cyclophosphamide (D-18864) and
glufosfamide (D-19575,$-D-glucose-isophospho-
ramide mustard) were obtained from NIOMECH
(Bielefeld, Germany). D-17272, D-18864 and
D-19575 were dissolved in aqua pro injectione
(Polpharma). All solutions were freshly prepared
directly before treatment of the leukemic HL-60
cells.
Oxazaphosphorine doses and cell treatment
After a dilution of the cell suspension to a den-
sity of 15x104 cells/ml medium, HL-60 cells were
subjected to a 60 min oxazaphosphorine agent ex-
posure. D-18864 was given at a dose of 10 Fg/ml
medium, D-19575 at a dose of 100Fg/ml medium,
and D-17272 was applied in two doses: 10 Fg/ml
and 100 Fg/ml medium. The control material con-
sisted of untreated HL-60 cells. After a 60 min
treatment with the oxazaphosphorine agent, leukemic
cells were centrifuged at 1000 rpm (MPW-360R
centrifuge, Med. Instruments) for 10 min, and the
supernatant was discarded. The cells were then
washed in 2 ml of PBS (BioMed) and pelletted by
centrifugation for 7 min. The wash and centrifuga-
tion were repeated once more and the cells were re-
suspended in the complete RPMI 1640 medium.
Analyses of HL-60 cells after oxazaphosphorine
application
Temporary changes occurring in human pro-
myelocytic leukemia HL-60 cells were deter-
mined at 24, 48, and 72 h after cell exposure to the
oxazaphosphosphorine agent. At these three time
intervals, the cell viability, volume and count, and
also the frequency of cells undergoing mitotic ca-
tastrophe, apoptosis and necrosis, were analyzed.
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Fig. 1. The chemical structures of the three oxazaphosphorine agents D-18864, D-17272, and D-19575.
In vitro spectrophotometric MTT assay
In viable, metabolically active cells, the tetra-
zolium ring of MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide) is cleaved,
yielding formazan crystals. Changes in the meta-
bolic activity of cell populations result in a concomi-
tant change in the amount of formazan formed.
MTT (Sigma-Aldrich) was dissolved in RPMI
1640 medium, at a concentration of 5 mg/ml, and
filtered through a 0.2Fm filter. 100Fl of the yellow
MTT solution was added to each well of a 24-well
plate, containing 1 ml of the cell suspension, and
the cells were incubated at 37°C with 5% CO2. The
blank solution was prepared according to the
above procedure using complete medium without
cells. After the three-hour incubation period, the
resulting formazan crystals were dissolved with
1 ml of acidified isopropanol (0.05 N HCl in abso-
lute isopropanol). Absorbance of the obtained so-
lution was measured at a wavelength of 570 nm
using a Pharmacia Ultrospec III spectrophotome-
ter (Pharmacia). The extent of MTT conversion in
cells was also expressed as a percentage value of
the control.
Measurement of HL-60 cell size and count
The Beckman Coulter method of cell sizing and
counting is based on the detection of an electrical
pulse which results from the passage of each cell
through an aperture. The amplitude of the pro-
duced electrical pulse depends on the cell volume.
The number of pulses indicates the cell count.
Samples of HL-60 cell suspension were taken
from flasks and immediately diluted in ISOTON II
(Beckman Coulter filtered electrolyte solution
based on 0.9 % saline). 500 Fl of the cell suspen-
sion was added to 4.5 ml of ISOTON II. After the
dilution of the leukemic cell suspension, individual
HL-60 cells were measured using a Z2 Coulter
counter (Beckman Coulter, USA). The volume
and count distribution of HL-60 cells was obtained
using a counter equipped with a 100 Fm diameter
orifice. The flow rate was 500 Fl / 12.5 sec. The
range for cell measurement was determined as
268-7346 fL. The cell volume and count was ana-
lyzed at 832-7346 fL. The instrument was calibrated
using 10Fm diameter latex beads (Beckman Coul-
ter CC size standard). The mean cell volume and
the cell count were determined using Z2 Accu-
Comp software (Beckman Coulter, USA).
Microscopy analysis of HL-60 cells
HL-60 cell suspension, eventually diluted in
HBBS (GIBCO BRL Life Technologies), contain-
ing approximately 2x105 cells, was added into
a cytospin chamber and centrifuged at 1000 rpm
(MPW-350R centrifuge, Med. Instruments) for
6 min, at 4ºC. After air drying, the prepared cyto-
spins were fixed in a mixture of ethanol and acetic
acid solution (9:1), at room temperature for 30 min.
Immediately before staining, the slides with the
fixed cells were rinsed with PBS (BioMed). The
cytospins were stained with a dye solution contain-
ing 1 Fg/ml of 4’-6’-diamino-2-phenylindole
(DAPI) and sulforhodamine 101 (Sigma Aldrich),
for 3-5 min. The slides were then rinsed in PBS and
the cytospins were mounted under a coverslip in
a drop of PBS.
Three cytospins from each experimental group,
stained with DAPI and sulforhodamine 101, were
examined under 400x magnification, using a Jena-
val epifluorescent microscope (Carl Zeiss, Ger-
many). Based on the morphology of leukemic
cells, the frequency of HL-60 cells undergoing mi-
totic catastrophe, apoptosis, and necrosis was cal-
culated. The incidence of cells with mitotic
catastrophe, apoptotic and necrotic cells among
9000 HL-60 cells (3000 cells per slide) was deter-
mined.
The cells undergoing mitotic catastrophe ex-
press multiple mitotic abnormalities, such as mis-
segregation and condensation of chromosomes,
and chromosome alignment defects. Mitotic catas-
trophe is also characterized by the formation of
multinucleated giant cells with uncondensed ab-
normal nuclei, and also micronuclei (MANSILLA et
al. 2006; RICCI & ZONG 2006). The features of
apoptosis include cell shrinkage, chromatin con-
densation, nuclear fragmentation, and cell disas-
sembly into apoptotic bodies. Characteristic
features of necrosis are cell swelling, complete
morphological cell disintegration, membrane rup-
ture and the release of cell content (RAFFRAY &
COHEN 1997; PROSKURYAKOV et al. 2002; RICCI
& ZONG 2006; DE BRUIN & MEDEMA 2008). The
morphological criteria described above discrimi-
nated between leukemic cells which underwent
mitotic catastrophe, apoptosis, and necrosis.
Statistical evaluation
Statistical significance of differences in the
amount of formazan formed, the cell volume and
count, and in the frequency of cells undergoing mi-
totic catastrophe, apoptosis, and necrosis, were
evaluated by an analysis of variance and Duncan’s
new multiple range test. A difference with P<0.05
was considered statistically significant. The re-
sults were confirmed by three independent experi-
ments carried out in triplicate.
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Results
Effects of oxazaphosphorines on HL-60 cells
We determined the influence of new generation
oxazaphosphorines D-17272, D-18864 and
D-19575 on human promyelocytic leukemia
HL-60 cells. The effects of these three oxazaphos-
phorine agents on cell viability (Table 1, Fig. 2),
cell size (Table 2, Fig. 3) and count (Table 3), the
induction of mitotic catastrophe (Table 4, Fig. 4),
the triggering of apoptosis (Table 5, Fig. 4) and ne-
crosis (Table 6, Fig. 4) were compared.
Cell viability
The leukemic cell viability was correlated with
the optical density of the formazan solution. In
comparison with the controls, the optical density
of the formazan solution decreased 24h, 48h, and
72h after treatment of HL-60 cells with D-18864,
D-17272, and at 24h and 72h after leukemic cell
exposure to the action of D-19575. Among HL-60
cells treated with the oxazaphosphorines, the
smallest values of the optical density of the formed
formazan were found following D-17272 applica-
tion at a dose of 100 Fg/ml. The values of the opti-
cal density of the formazan solution appeared
greater when D-17272 was given at a dose of
10 Fg/ml medium, as compared with values ob-
tained after D-18864 application at the same dose.
Moreover, greater optical density of formazan was
observed after treatment of HL-60 cells with
D-19575 than when D-17272 was applied at
the same dose of 100Fg/ml medium (Table 1). The
viability rate, expressed as a percentage value of
the control, appeared to be distinctly decreased in
HL-60 cells treated with D-18864, and especially
in leukemic cells exposed to the action of D-17272
at a dose of 100 Fg/ml medium (Fig. 2).
Cell size
In relation to the controls, the mean volume of
HL-60 cells increased in all the remaining experi-
Fig. 2. Effects of oxazaphosphorines on the viability rate of
HL-60 cells. The extent of MTT conversion to formazan in
HL-60 cells, expressed as a percentage value of the control.
Table 1
The optical density of formazan solution determined in HL-60 cells after their exposure to
the oxazaphosphorine agents
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Optical density of formazan solution (x10-2)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 3, 4, 5, 48h, 72h
16.25 ± 0.97
2, 3, 4, 5, 24h, 72h
26.71 ± 1.09
2, 3, 4, 5, 24h, 48h
31.91 ± 2.03
II D-17272 10 Fg/ml
1, 3, 4, 5, 48h, 72h
19.35 ± 0.48
1, 3, 4, 5, 24h, 72h
34.27 ± 1.08
1, 3, 4, 5, 24h, 48h
43.08 ± 1.64
III D-17272 100 Fg/ml
1, 2, 4, 5, 48h, 72h
13.84 ± 0.69
1, 2, 4, 5, 24h, 72h
20.45 ± 1.11
1, 2, 4, 5, 24h, 48h
25.75 ± 0.74
IV D-19575 100 Fg/ml
1, 2, 3, 5, 48h, 72h
18.59 ± 0.88
1, 2, 3, 24h, 72h
38.16 ± 1.20
1, 2, 3, 5, 24h, 48h
53.92 ± 1.09
V Control
1, 2, 3, 4, 48h, 72h
21.23 ± 1.31
1, 2, 3, 24h, 72h
39.57 ± 1.15
1, 2, 3, 4, 24h, 48h
58.82 ± 1.32
The data are presented as mean values ± standard deviation.
Statistically significant differences at P<0.05
Differences between experimental groups: different from Group I – 1; Group II – 2; Group III – 3; Group IV – 4; Group V – 5.
Differences within each experimental group: different from 24h – 24h; 48h – 48h; 72h –72h.
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Fig. 3. The mean volume of HL-60 cells after their exposure to the action of three oxazaphosphorine agents. The peaks on the left
represent cellular debris, presumably apoptotic bodies and necrotic cell fragments, which were excluded from the analysis of
HL-60 cell volume. 10 – the oxazaphosphorine agent applied at a dose of 10 Fg/ml medium; 100 – the oxazaphosphorine agent
applied at a dose of 100 Fg/ml medium.
Fig. 4. Effects of oxazaphosphorines on human promyelocytic leukemia HL-60 cells. Morphology of HL-60 cells observed 72h
after their exposure to the action of the three oxazaphosphorine agents D-18864, D-17272 and D-19575. The leukemic HL-60
cells, stained with the DNA specific fluorochrome DAPI and the protein fluorochrome sulforhodamine 101, are visible under
a Zeiss fluorescence microscope. Hallmarks of mitotic catastrophe, apoptosis, and necrosis were given in the methodology
section. Scale bar – 20 Fm.
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mental groups and at all three time intervals, i.e.
24h, 48h, and 72h after exposure to oxazaphos-
phorines. Among the oxazaphosphorine tested, the
smallest mean volume of HL-60 cells was ob-
served when D-19575 was applied at a dose of 100
Fg/ml medium. Larger values of mean cell volume
were found 48h after D-18864 and D-17272 appli-
cation, at a dose of 10Fg/ml medium, and 72h after
leukemic cell exposure to D-17272 at a dose of 100
Fg/ml medium, compared to values obtained at the
remaining time intervals (Table 2).
Table 2
The mean volume of HL-60 cells after their exposure to oxazaphosphorine agents
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Mean Cell Volume (fL)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 3, 4, 5, 48h, 72h
3 246 ± 73
2, 3, 4, 5, 24h, 72h
4 594 ± 80
2, 3, 4, 5, 24h, 48h
3 842 ± 36
II D-17272 10 Fg/ml
1, 3, 4, 5, 48h
3 534 ± 49
1, 3, 4, 5, 24h, 72h
4 473 ± 63
1, 3, 4, 5, 48h
3 557 ± 88
III D-17272 100 Fg/ml
1, 2, 4, 5, 48h, 72h
2 882 ± 28
1, 2, 4, 5, 24h, 72h
3 923 ± 90
1, 2, 4, 5, 24h, 48h
4 381 ± 87
IV D-19575 100 Fg/ml
1, 2, 3, 5, 48h, 72h
2 629 ± 28
1, 2, 3, 5, 24h, 72h
2 789 ± 27
1, 2, 3, 5, 24h, 48h
2 333 ± 28
V Control
1, 2, 3, 4, 48h, 72h
2 106 ± 26
1, 2, 3, 4, 24h, 72h
2 227 ± 15
1, 2, 3, 4, 24h, 48h
1 933 ± 22
For explanation of signs see Table 1.
Table 3
The count of HL-60 cells after their exposure to oxazaphosphorine agents
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Cell count (x103)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 4, 5, 48h, 72h
167.99 ± 9.31
2, 4, 5, 24h, 72h
150.42 ± 6.26
2, 4, 5, 24h, 48h
96.50 ± 4.13
II D-17272 10 Fg/ml
1, 3, 4, 5, 72h
194.23 ± 5.20
1, 3, 4, 5, 72h
208.37 ± 10.91
1, 3, 4, 5, 24h, 48h
432.26 ± 8.20
III D-17272 100 Fg/ml
2, 4, 5, 72h
158.33 ± 6.85
2, 4, 5, 72h
151.00 ± 7.97
2, 4, 5, 24h, 48h
102.68 ± 7.09
IV D-19575 100 Fg/ml
1, 2, 3, 5, 48h, 72h
278.73 ± 10.92
1, 2, 3, 5, 24h, 72h
637.00 ± 20.97
1, 2, 3, 5, 24h, 48h
1 036.55 ± 16.58
V Control
1, 2, 3, 4, 48h, 72h
345.95 ± 22.07
1, 2, 3, 4, 24h, 72h
846.75 ± 17.72
1, 2, 3, 4, 24h, 48h
1 315.65 ± 35.01
For explanation of signs see Table 1.
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Cell count
In comparison with the controls, the cell count of
HL-60 cells decreased in all the remaining experi-
mental groups and at all time intervals (24, 48h,
and 72h) after oxazaphosphorine application.
Among HL-60 cells, the highest cell number was
encountered when D-19575 was given at a dose of
100 Fg/ml medium. After the treatment of HL-60
cells with D-17272 at two doses of 10 Fg/ml and
100 Fg/ml medium, the cell count appeared to be
reduced in a dose-dependent manner. D-18864
given at a dose of 10 Fg/ml caused a greater de-
crease of the leukemic cell number than D-17272
applied at the same dose (Table 3).
Mitotic catastrophe
In comparison with the controls, the yield of mi-
totic catastrophe increased in all the remaining ex-
perimental groups and at all three time intervals
(24h, 48h, and 72h) after HL-60 cell exposure to
the tested oxazaphosphorines. The frequency of
the leukemic cells undergoing mitotic catastrophe
increased over time after application of D-18864
and D-17272, and decreased over time when
D-19575 was given. The highest yield of mitotic
catastrophe was observed 72h after the treatment
of HL-60 cells with D-17272 at a dose of 10 Fg/ml
medium (Table 4).
Apoptosis
In relation to the controls, the frequency of apop-
totic HL-60 cells increased in all the remaining ex-
perimental groups and at all three time intervals
(24h, 48h, and 72h) after leukemic cell exposure to
the oxazaphosphorine agents. Among the
oxazaphosphorines tested, the lowest frequency of
HL-60 cells undergoing apoptosis was found
when D-19575 was applied. The effects of
D-17272 on apoptosis-induction in HL-60 cells
was dose-dependent. The frequency of apoptotic
cells was lower after D-17272 application at a dose
of 10 Fg/ml medium than when D-18864 was
given at the same dose (Table 5).
Necrosis
In comparison with the controls, a higher fre-
quency of HL-60 cells undergoing necrosis was
found in all the remaining experimental groups
and at all three time intervals (24h, 48h, and 72h)
after the application of oxazaphosphorine. Among
the tested oxazaphosphorines, the lowest fre-
quency of necrotic cells was found after exposure
of HL-60 cells to the action of D-19575. After
treatment of the leukemic cells with D-17272 at
two doses of 10 Fg/ml and 100 Fg/ml medium, the
yield of necrosis increased in a dose-dependent
Table 4
The frequency of HL-60 cells undergoing mitotic catastrophe after oxazaphosphorine appli-
cation
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Frequency of cells undergoing mitotic catastrophe (%)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 3, 5, 48h, 72h
5.74 ± 0.57
3, 4, 5, 24h, 72h
8.87 ± 1.70
2, 3, 4, 5, 24h, 48h
12.50 ± 1.49
II D-17272 10 Fg/ml
1, 3, 4, 5, 48h, 72h
4.46 ± 0.51
3, 4, 5, 24h, 72h
9.67 ± 1.05
1, 3, 4, 5, 24h, 48h
15.12 ± 1.19
III D-17272 100 Fg/ml
1, 2, 4, 5, 48h, 72h
3.33 ± 0.21
1, 2, 5, 24h, 72h
6.42 ± 1.05
1, 2, 4, 5, 24h, 48h
10.60 ± 1.04
IV D-19575 100 Fg/ml
2, 3, 5, 72h
6.21 ± 0.68
1, 2, 5, 72h
5.47 ± 0.71
1, 2, 3, 5, 24h, 48h
1 036.55 ± 16.58
V Control
1, 2, 3, 4
0.92 ± 0.18
1, 2, 3, 4
1.04 ± 0.17
1, 2, 3, 4
1.09 ± 0.27
For explanation of signs see Table 1.
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manner. Necrotic death was induced in HL-60
cells to a greater degree when D-18864 was given
at a dose of 10 Fg/ml than when D-17272 was ap-
plied at the same dose (Table 6).
Discussion
In the present study, the activity of the new ge-
neration oxazaphosphorines, D-17272, D-18864
and D-19575, against human promyelocytic leu-
Table 5
The frequency of HL-60 cells undergoing apoptosis after oxazaphosphorine application
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Frequency of cells undergoing apoptosis (%)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 4, 5, 48h, 72h
3.74 ± 0.95
2, 3, 4, 5, 24h, 72h
4.59 ± 1.01
2, 4, 5, 24h, 48h
6.04 ± 1.44
II D-17272 10 Fg/ml
1, 3, 4, 5
2.56 ± 0.36
1, 3, 4, 5
2.70 ± 0.54
1, 3, 4, 5
3.10 ± 0.78
III D-17272 100 Fg/ml
2, 4, 5, 72h
3.23 ± 0.67
1, 2, 4, 5, 72h
3.66 ± 0.75
2, 4, 5, 24h, 48h
5.53 ± 0.80
IV D-19575 100 Fg/ml
1, 2, 3, 5
1.20 ± 0.29





1, 2, 3, 4
0.54 ± 0.13




For explanation of signs see Table 1.
Table 6
The frequency of HL-60 cells undergoing necrosis after oxazaphosphorine application
Group characteristic
Time intervals after cell exposure to oxazaphosphorines
24h 48h 72h
No. Agent given Agent dose
Frequency of cells undergoing necrosis (%)
Mean ± SD Mean ± SD Mean ± SD
I D-18864 10 Fg/ml
2, 4, 5, 48h, 72h
5.31 ± 1.18
2, 3, 4, 5, 24h
6.74 ± 1.25
2, 3, 4, 5, 24h
7.57 ± 1.04
II D-17272 10 Fg/ml




1, 3, 5, 24h
5.18 ± 1.29





1, 2, 4, 5, 24h, 48h
6.21 ± 1.21
IV D-19575 100 Fg/ml




1, 3, 5, 24h
4.28 ± 0.95
V Control
1, 2, 3, 4
0.87 ± 0.21
1, 2, 3, 4
0.91 ± 0.24
1, 2, 3, 4
1.01 ± 0.20
For explanation of signs see Table 1.
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kemia HL-60 cells was evaluated. Various pat-
terns of temporary changes in cell viability, size
and count, and in the frequency of cells undergo-
ing mitotic catastrophe and programmed cell
death, were found at 24h, 48h and 72h after expo-
sure of HL-60 cells to the action of these three
oxazaphosphorine agents. The results obtained in
the present investigation and previous studies
point to the varied action of D-18864, D-17272,
and D-19575 on pathological hematopoietic cells.
The damage caused by these alkylating agents in
HL-60 cells was manifested as decreased cell
viability, different cell volume distribution, re-
duced cell count, induction of mitotic catastrophe,
and triggering apoptotic and necrotic cell death.
The decreased viability rate and a reduced count of
MOLT-4 cells and ML-1 cells treated with
oxazaphosphorines were also observed by OPYDO-
CHANEK et al. (2011) and MAZUR et al. (2012b).
The effects of D-18864, D-17272 and D-19575 on
mitotic catastrophe-induction in U937 cells was
demonstrated by MAZUR et al. (2009). The influ-
ence of the cyclophosphamide analogue mafosfa-
mide on triggering apoptotic death in human
lymphoblastoid cells was reported by GOLDSTEIN
et al. (2008). The size distribution of MOLT-4
cells, U-937 cells and ML-1 cells exposed to
oxazaphosphorines was shown by OPYDO-CHANEK
et al. (2010, 2011) and MAZUR et al. (2012b). The
human leukemic cell response to the action of
D-17272, D-18864 and D-19575 found in the pre-
vious and present investigations appeared to be de-
pendent on the agent tested and its dose, the time
intervals after oxazaphosphorine application and
the cell line used (MAZUR et al. 2009, 2010,
2012b; OPYDO-CHANEK et al. 2010, 2011).
The alterations observed in the leukemic cells
following their exposure to D-18864, D-17272
and D-19575 surely resulted from abnormal pro-
cesses occurring at the molecular, biochemical,
and cellular levels. The exact mechanisms of ac-
tion of the three oxazaphosphorine agents are al-
most entirely unknown (BODY & YULE 2000;
ZHANG et al. 2005b; LIANG et al. 2007). What is
known is that D-18864, 4-hydro-peroxy-cyclo-
phosphamide generates its active principle 4-hydroxy-
cyclophosphamide (4-OH-CP). D-17272, a ma-
fosfamide cyclohexylamine salt, generates 4-OH-CP.
Phosphoramide mustard and acrolein are the ma-
jor reactive alkylating agents of the two prodrugs
D-18864 and D-17272. $-D-glucose-isopho-
sphoramide mustard, D-19575, contains the di-
rectly reactive alkylating moiety, isophosphora-
mide mustard. These reactive alkylating agents are
responsible for the cytotoxicity of oxazaphos-
phorines. The anticancer activity of D-18864,
D-17272 and D-19575 is believed to also be de-
pendent on the pharmacokinetic and pharmacody-
namic properties of these alkylating agents due to
their different chemical structure (BODY & YULE
2000; ENGEL et al. 2000; SEKER et al. 2000;
ZHANG et al., 2005a, 2005b; LIANG et al. 2007;
MAZUR et al. 2011, 2012a).
In summary, the results of the present study are
the first data comparing the potential of the three
oxazaphosphorines, D-17272, D-18864, and D-19575,
to induce mitotic catastrophe and programmed
death, and affect the viability, size and count of hu-
man promyelocytic leukemia HL-60 cells. An elu-
cidation of the mechanisms responsible for the
various activities of the new generation oxaza-
phosphorine agents against the different types of
pathological hematopoietic cells can provide the
rationale for their optional use in chemotherapy.
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